微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 48.56% | 4.65% | 8.99% | 73/158 | 32.3% | 华特达因 | 85.78% | 行业排名> |
| 2024-12-31 | 44.55% | -2.74% | -4.72% | 92/158 | 51.8% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 46.76% | 1.97% | -0.05% | 83/158 | 22.73% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 46.78% | 2.59% | 0.82% | 85/158 | 33.18% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 46.4% | -0.07% | 1.3% | 83/158 | 51.56% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 45.81% | 5.24% | -0.11% | 93/158 | 51.38% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 45.86% | 5.63% | 0.56% | 91/158 | 32.56% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 45.6% | 4.77% | -1.79% | 91/158 | 38.45% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 46.43% | 3.82% | 6.68% | 86/158 | 52.78% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 43.53% | 1.82% | 0.26% | 94/158 | 53.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 43.41% | -0.47% | -0.26% | 91/158 | 6.2% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 43.53% | -2.67% | -2.68% | 93/158 | 21.37% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 44.72% | -1.55% | 4.62% | 83/158 | 54.28% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 42.75% | 1.84% | -1.99% | 94/158 | 55.1% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 43.62% | 2.58% | -2.46% | 84/158 | 46.78% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 44.72% | 7.75% | -1.57% | 84/158 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 45.43% | 5.41% | 8.23% | 76/158 | 53.99% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 41.97% | 6.21% | -1.28% | 101/158 | -145.9% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 42.52% | 8.23% | 2.46% | 85/158 | 56.36% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 41.5% | 5% | -3.7% | 92/158 | 54.11% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 43.1% | 7.52% | 9.05% | 78/158 | 55.23% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 39.52% | -1.02% | 0.6% | 100/158 | -1222.98% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 39.29% | -1.5% | -0.61% | 79/158 | 55.21% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 39.53% | -1.34% | -1.38% | 82/158 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 40.08% | -2.28% | 0.39% | 75/158 | 51.05% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 39.93% | 4.85% | 0.11% | 97/158 | -208.09% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 39.88% | 1.96% | -0.45% | 71/158 | 53.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 40.06% | 3.69% | -2.33% | 72/158 | 53.39% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 41.02% | 4.78% | 7.72% | 68/158 | 53.9% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 38.08% | 3.52% | -2.65% | 81/158 | 52.32% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 39.12% | 7.41% | 1.23% | 62/158 | 49% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 38.64% | 7.6% | -1.29% | 66/158 | 47.74% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 39.15% | 8.22% | 6.41% | 50/158 | 46.55% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 36.79% | 1.22% | 1.01% | 76/158 | 48.19% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 36.42% | -2.07% | 1.41% | 50/158 | 45.76% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 35.91% | -4.26% | -0.72% | 60/158 | 45.89% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 36.17% | -5.25% | -0.47% | 49/158 | 43.5% | 微芯生物 | 97.46% | 行业排名> |
| 2015-12-31 | 36.35% | -12.05% | -2.27% | 67/158 | 45.97% | 贝达药业 | 97.01% | 行业排名> |
| 2015-09-30 | 37.19% | -10.51% | -0.85% | 46/158 | 44.69% | 贝达药业 | 97.02% | 行业排名> |
| 2015-06-30 | 37.51% | -9.94% | -1.75% | 49/158 | 45% | 舒泰神 | 94.38% | 行业排名> |
| 2015-03-31 | 38.18% | -6.76% | -7.62% | 44/158 | 43.46% | 贝达药业 | 96.95% | 行业排名> |